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Introduction: Adenoid cystic carcinoma of Bartholin’s gland is a very rare disease.
Case presentation: A 48-year-old premenopausal woman of Caucasian origin was delivered adjuvant pelvic and
inguinal radiotherapy after prior complete left Bartholin’s gland tumor excision and inguinal lymph node dissection
for adenoid cystic carcinoma of Bartholin’s gland with one metastatic inguinal lymph node.
Two years after primary treatment, she presented to the Emergency Room with acute headache, hypoacousia,
decrease in visual acuity, and a decrease in right leg muscle strength. A cranial magnetic resonance imaging scan
demonstrated three cystic brain lesions with associated perifocal edema. Chest and abdomen computed
tomography scans and a magnetic resonance imaging scan of the pelvis did not find any metastatic or residual
disease elsewhere. A physical examination found no local recurrence.
Stereotactic brain biopsies with pathology examination revealed the presence of adenoid cystic carcinoma
metastasis. She thus received 30Gy of brain radiotherapy but, three months later, the brain lesions did not decrease
in size and left mid lobular lung lesions appeared on her chest computed tomography scan. A mid left lobe lung
excision was undertaken followed by chemotherapy consisting of six cycles of cyclophosphamide, adriamycin and
cisplatin. Five months after beginning chemotherapy, the brain disease progressed and our patient died.
Conclusion: Our case report shows the difficulty in managing brain and lung metastasis of Bartholin’s gland
adenoid cystic carcinoma as no consensus on the optimal treatment exists.
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Bartholin’s gland carcinoma is a rare disease, accounting
for 0.1% to 5% of all vulval carcinomas and representing
barely 0.001% of gynecological cancers [1]. Different
histological variants have been described: adenocarcin-
omas, squamous cell carcinomas, transitional cell carcin-
omas and adenoid cystic carcinomas. The latter represent
10% to 15% of Bartholin’s gland tumors and arise usually
from salivary, lacrimal and nasopharynx glands, and some-
times from mammary, skin and uterine cervix glands
[2]. The mean age at diagnosis is around 50 years with
a range between 25 and 80 years [3]. Distant metastasis
has been found in only a few cases to the lungs, liver
and brain. Here, we present the first case of Bartholin’s
gland adenoid cystic carcinoma (ACC) with metastasis
to the brain and lung.* Correspondence: rajeev.ramanah@univ-fcomte.fr
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In May 2009, a 48-year-old gravida 1 para 1 premenopausal
woman of Caucasian origin presented with a tender mass
in the area of the left Bartholin’s gland, associated with
a left palpable inguinal lymph node, which had been
slowly evolving for two years. Following the tumor’s recent
increase in size and vulval pain, a left Bartholin’s gland
excision (bartholinectomy) was performed under general
anesthesia.
The pathology examination revealed a primitive ACC
of Bartholin’s gland measuring 30mm but with positive
margins.
Upon diagnosis of this unexpected malignant lesion, a
systematic search for metastatic disease was undertaken.
Chest, abdomen and pelvis computed tomography (CT)
scans with intravenous contrast along with a magnetic
resonance imaging (MRI) scan of the pelvis showed a
highly suspicious left inguinal lymph node demonstrating
high metabolic activity upon whole body positron emissional Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Next, our patient underwent radical tumor re-excision
with left inguinofemoral lymph node dissection. The post-
operative pathology examination found two remaining
tumors of 6mm close to the surgical margin. Tumor
cavity vaginal and vestibular re-excisions were clearly
disease-free. Among the seven inguinofemoral lymph
nodes collected, one of them, measuring 45mm with an
intact capsule, had metastatic disease.
Postoperatively, after multidisciplinary discussion of the
case, adjuvant pelvic and inguinal radiotherapy was recom-
mended. She thus obtained 66Gy of radiation.
Follow-up visits were organized every three months with
CT scans of the chest, abdomen and pelvis performed
every six months. In June 2011, two years after her
primary treatment, she presented to the Emergency Room
with acute headache, hypoacousia, decrease in visual
acuity, and a decrease in right leg muscle strength.
A cranial MRI scan demonstrated three cystic brain
lesions in the right parietal, left parieto-occipital and left
temporal region with associated perifocal edema (Figure 1).
Chest and abdomen CT scans and a MRI scan of the
pelvis did not find any metastatic or residual disease
elsewhere. A physical examination found no local recurrence.
Stereotactic brain biopsies were undertaken. A pathology
examination revealed the presence of ACC metastasis with
characteristic tumor proliferation in a cribriform pattern
composed of nests and columns of cells arranged concen-
trically around gland-like spaces filled with eosinophilic
periodic acid-Schiff-positive material. These results were
confirmed after immunological staining with specific anti-
bodies, which showed that the brain lesions had similar
characteristics as the initial ACC of Bartholin’s gland
that was diagnosed two years earlier (Figure 2). Immu-
nohistochemical characteristics were: cytokeratin (CK)
AE1/AE3 positive, CK7 positive, epithelial membrane
antigen (EMA) positive, S100 weakly positive, CK20Figure 1 Gadolinium-enhanced axial T1-weighted brain
magnetic resonance imaging scans showing three metastatic
cystic brain lesions in the right parieto-occipital and temporal
regions with associated perifocal edema.negative, estrogen receptor negative, progesterone recep-
tor weakly positive.
Our patient’s case was once again discussed at a multi-
disciplinary meeting where whole brain radiotherapy
was advocated. The patient thus received 30Gy of brain
radiotherapy ending in August 2011. A cranial MRI scan,
chest and abdomen CT scans, and a MRI scan of the
pelvis were performed three months later to evaluate the
efficacy of the treatment. The brain lesions had not de-
creased in size and right middle lobe lung lesions appeared
on the chest CT scan (Figure 3). A whole body PET scan,
pelvic imaging and examination did not show any local
recurrence or other metastatic lesions.
A lung biopsy with an extemporaneous examination
followed by a middle right pulmonary lobe excision was
undertaken. A postoperative pathologic examination con-
firmed the diagnosis of ACC lung metastasis. Afterward,
our patient received chemotherapy consisting of cyclo-
phosphamide, cisplatin and adriamycin. Five months after
beginning chemotherapy, the brain disease progressed
with the appearance of frequent seizures upon increased
cerebral edema, and our patient died.
Discussion
An ACC of the Bartholin’s gland presents itself with
similar symptoms as most vulval cancers. Patients usually
complain of pruritus, a burning sensation and pain, which
are explained by this slow-growing tumor’s tendency for
local and perineural invasion. These symptoms can even
be experienced before the physical appearance of any
vulval mass. Among other nonspecific signs like bleeding,
dyspareunia, and/or discharge from an abscess [4], the
presence of an inguinal lymph node should be considered
as being highly suspicious of malignancy. However, in
most cases of symptomatic Bartholin’s cysts, patients will
be treated with only drainage and marsupialization as the
diagnosis of a benign condition is expected. That is why
some authors recommended performing fine-needle aspir-
ation cytology before or during surgery, especially in
women over the age of 40 [5]. However, the diagnostic
value of cytology is poor. Moreover, the overall incidence
of Bartholin gland carcinoma has been found to be low
and similar in pre- and postmenopausal women [6].
Advocating systematic excision of a Bartholin’s cyst would
probably create excess morbidity and complications asso-
ciated with radical procedures while the primary surgery
would still result in inadequate margin status. A reason-
able approach to the management of any patient with
Bartholin gland mass may be to incise, drain and obtain
multiple biopsies to rule out any underlying carcinoma. In
our case report, a reintervention was necessary for positive
margins and inguinofemoral lymphadenectomy although
a complete Bartholin gland excision was performed as
the primary treatment. Radical vulvectomies should not
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Figure 2 Histology of the brain metastasis biopsy specimen. (A) Hematoxylin and eosine stain with magnification x 200: adenoid cystic
carcinoma cells (purple) adjacent to normal brain tissue (pink) at the upper left. (B) Hematoxylin and eosine stain with magnification x 400: adenoid
cystic carcinoma cells (purple) arranged in a typical cribriform pattern, forming columns around gland-like spaces. (C) Immunohistochemistry with
anti-cytokeratin 7 antibodies showing a typical positive stain for adenoid cystic carcinoma cells.
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similar in patients with positive and negative margins,
explained in part by adjuvant radiotherapy being preferen-
tially proposed in case of inadequate margin status [4].
Instead, surgery and radiotherapy should be tailored to
the extent and location of the tumor so as to decrease
morbidity and to maintain an acceptable quality of life
without compromising the survival rate, as reported in
a survey over 20 years [7].
This case report, with metastatic brain and lung dis-
eases, especially without any local recurrence, does not
correspond to the usual presentation of ACC, except for
the age at diagnosis. In a review of the literature published
by Alsan et al. [8], the lungs were found to be the most
common site of distant metastasis, followed by the liver
and less frequently the bone. Until now, only one case
of brain metastasis has been described in the English
literature [9]. ACC is known to have high rates of local
recurrence estimated at 30% and with a risk of distant
metastasis being at 31% [8]. Ten-year disease-free interval
and survival rates are respectively 38% and 50% [4]. Here,
no local recurrence was observed, possibly because our
patient had an optimal local surgical and radiation
treatment, but brain metastasis occurred two years
after primary treatment.
Brain metastases from gynecological cancers are rare,
and usually occur in cases of widely disseminated carcin-
omas through the bloodstream or the lymphatic system.Figure 3 Frontal and axial chest computed tomography scans showin
middle lobe of the lung.In our case, it is most probably through the lymphatic
system that tumor cells metastasized to the brain. In the
previous case report of Bartholin’s gland, ACC brain me-
tastasis was described as a single lesion in the cerebellar
vermis [9]. The authors were thus able to surgically
remove the lesion before whole brain radiotherapy. How-
ever, postoperatively, the patient experienced tetraplegia
and an MRI scan revealed residual tumors in the vermis,
the cerebellar and cerebral cortices. These residual brain
lesions were decreased with radiotherapy. It was not clear
whether surgery was responsible for the seeding metasta-
ses or new cortical lesions developed postoperatively.
Hatiboglu et al. demonstrated that brain metastasis
from an ACC of the Bartholin gland responded well to
radiotherapy at a total dose of 30Gy but the follow-up
interval was only one month [9]. We could not find
the same efficacy, probably because of the presence of
multiple lesions that could not be surgically removed.
Indeed, a randomized controlled trial showed that patients
with a single brain metastasis treated with surgery and
radiotherapy had a longer survival and a lower recurrence
rate than patients treated with radiotherapy alone [10].
However, in cases of multiple or inoperable brain metasta-
ses, whole brain radiotherapy is recommended [10]. In the
present case, there were three lesions in the cerebral cor-
tex making surgery difficult and risky. Thus radiotherapy
as a primary treatment proved inadequate since it had no
effect on the brain lesions and lung metastasis appeared.g adenoid cystic carcinoma metastasis (red arrow) in the right
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helped control disease progression in the lungs but the
disease progressed in the brain. Previous management
of lung metastasis showed that surgery alone was not
sufficient [4]. Several chemotherapeutic regimens have
been reported in the literature but the use of cyclophos-
phamide, adriamycin and cisplatin seems most common
[4,11].
Conclusions
The prognosis of ACC with brain and lung metastasis is
poor. Although, local and distant recurrences of ACC
have been reported to be radiosensitive [12], we did not
achieve any disease control. It is actually not possible to
have large cohort or randomized studies on the ACC of
Bartholin’s gland because of its low prevalence, making
it difficult to obtain a consensus regarding its optimal
treatment. This case study showed that in cases of mul-
tiple brain metastases, radiotherapy alone is probably
not sufficient, thus raising the question of an early as-
sociation of chemotherapy.
Consent
Our patient died and next-of-kin was not traceable after
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following the conditions specified by the Committee on
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is no reason to believe that our patient would have
objected to publication.
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